Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Summary

The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Breast Cancer
• Metastatic Breast Cancer
• Advanced Breast Cancer
• Hormone-receptor-positive Breast Cancer
• Human Epidermal Growth Factor 2 Low Breast Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Reshma L. Mahtani, D.O.

Last updated on ClinicalTrials.gov

August 12, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites